Actinium Pharmaceuticals Inc (ATNM)
8.96
+0.21
(+2.40%)
USD |
NYAM |
May 03, 16:00
8.915
-0.04
(-0.50%)
After-Hours: 20:00
Actinium Pharmaceuticals Enterprise Value: 182.80M for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 182.80M |
| May 02, 2024 | 176.55M |
| May 01, 2024 | 147.66M |
| April 30, 2024 | 145.28M |
| April 29, 2024 | 135.75M |
| April 26, 2024 | 120.56M |
| April 25, 2024 | 108.78M |
| April 24, 2024 | 123.48M |
| April 23, 2024 | 120.54M |
| April 22, 2024 | 126.72M |
| April 19, 2024 | 117.31M |
| April 18, 2024 | 112.02M |
| April 17, 2024 | 129.07M |
| April 16, 2024 | 143.47M |
| April 15, 2024 | 164.05M |
| April 12, 2024 | 180.51M |
| April 11, 2024 | 183.16M |
| April 10, 2024 | 180.22M |
| April 09, 2024 | 179.92M |
| April 08, 2024 | 184.33M |
| April 05, 2024 | 196.38M |
| April 04, 2024 | 184.33M |
| April 03, 2024 | 175.81M |
| April 02, 2024 | 168.75M |
| April 01, 2024 | 167.58M |
| Date | Value |
|---|---|
| March 28, 2024 | 153.50M |
| March 27, 2024 | 156.73M |
| March 26, 2024 | 148.77M |
| March 25, 2024 | 164.04M |
| March 22, 2024 | 178.75M |
| March 21, 2024 | 176.25M |
| March 20, 2024 | 162.10M |
| March 19, 2024 | 151.27M |
| March 18, 2024 | 104.90M |
| March 15, 2024 | 110.73M |
| March 14, 2024 | 97.40M |
| March 13, 2024 | 109.34M |
| March 12, 2024 | 106.29M |
| March 11, 2024 | 115.45M |
| March 08, 2024 | 135.72M |
| March 07, 2024 | 134.61M |
| March 06, 2024 | 138.77M |
| March 05, 2024 | 139.05M |
| March 04, 2024 | 142.10M |
| March 01, 2024 | 158.49M |
| February 29, 2024 | 160.15M |
| February 28, 2024 | 154.04M |
| February 27, 2024 | 152.93M |
| February 26, 2024 | 154.04M |
| February 23, 2024 | 113.79M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
3.298M
Minimum
Jun 30 2022
257.21M
Maximum
Feb 16 2023
77.74M
Average
72.78M
Median
Enterprise Value Benchmarks
| Perspective Therapeutics Inc | 1.055B |
| Eli Lilly and Co | 722.23B |
| Cellectar Biosciences Inc | 106.83M |
| Outlook Therapeutics Inc | 211.81M |
| Bristol-Myers Squibb Co | 135.24B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.67M |
| Total Expenses (Quarterly) | 9.597M |
| EPS Diluted (Quarterly) | -0.31 |
| Earnings Yield | -19.08% |
| Normalized Earnings Yield | -20.42 |